Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients

• Status: Completed
• Trial end date: 2006-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

To evaluate clinical and pathologic response rates following primary hormonal therapy by exemestane (Aromasin®)

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Exemestane

Criteria

Inclusion Criteria:

• Post-menopausal patients with unilateral breast cancer T2 to T4, N0-1, M0, non inflammatory, operable, hormonal receptors positive

Exclusion Criteria:

• Patients with bilateral breast cancer T4d, inflammatory, non operable, hormonal receptors negative